Genotoxic stress modulates CDC25C phosphatase alternative splicing in human breast cancer cell lines

Molecular Oncology

Volumn 6, Issue 5, 2012, Pages 542-552

  Albert, Hélène ^a   Battaglia, Eric ^a   Monteiro, Carolino ^b   Bagrel, Denyse ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

Alternative splicing; ATM; ATR; Breast cancer cells; CDC25; CDC25 phosphatases; CDK; CPT; DAPI; Dox; DSB; Eto; Genotoxic stress; HnRNP; PARP; PFT ; SR

Indexed keywords

CAMPTOTHECIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; MESSENGER RNA; PHOSPHATASE; PHOSPHATASE CDC25C; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DNA DAMAGE; GENETIC VARIABILITY; GENOTOXIC STRESS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MODULATION; PRIORITY JOURNAL; STRESS;

EID: 84866006890     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.06.003     Document Type: Article

References (49)

1. Albert H., Santos S., Battaglia E., Brito M., Monteiro C., Bagrel D. Differential expression of CDC25 phosphatases splice variants in human breast cancer cells. Clin. Chem. Lab. Med. 2011, 49:1707-1714.
2. Aressy B., Ducommun B. Cell cycle control by the CDC25 phosphatases. Anticancer Agents Med. Chem. 2008, 8:818-824.
3. Baldin V., Cans C., Superti-Furga G., Ducommun B. Alternative splicing of the human CDC25B tyrosine phosphatase. Possible implications for growth control?. Oncogene 1997, 14:2485-2495.
4. Bartek J., Iggo R., Gannon J., Lane D.P. Genetic and immochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990, 5:893-899.
5. Biamonti G., Caceres J.F. Cellular stress and RNA splicing. Trends Biochem. Sci. 2009, 34:146-153.
6. Boutros R., Dozier C., Ducommun B. The when and wheres of CDC25 phosphatases. Curr. Opin. Cell. Biol. 2006, 18:185-191.
7. Boutros R., Lobjois V., Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets?. Nat. Rev. Cancer 2007, 7:495-507.
8. Bureik M., Rief N., Drescher R., Jungbluth A., Montenarh M., Wagner P. An additional transcript of the cdc25C gene from A431 cells encodes a functional protein. Int. J. Oncol. 2000, 17:1251-1258.
9. Busà R., Sette C. An emerging role for nuclear RNA-mediated responses to genotoxic stress. RNA Biol. 2010, 7:390-396.
10. Cailleau R., Young R., Olivé M., Reeves W.J.J. Breast tumor cell lines from pleural effusions. J. Natl. Cancer I 1974, 53:661-674.
11. Chandler D.S., Singh R.K., Caldwell L.C., Bitler J.L., Lozano G. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res. 2006, 66:9502-9508.
12. Chen M., Manley J.L. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat. Rev. Mol. Cell. Biol. 2009, 10:741-754.
13. Chen F., Zhang Z., Bower J., Lu Y., Leonard S.S., Ding M., Castranova V., Piwnica-Worms H., Shi X. Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:1990-1995.
14. Dalvai M., Mondesert O., Bourdon J.-C., Ducommun B., Dozier C. Cdc25B is negatively regulated by p53 through Sp1 and NF-Y transcription factors. Oncogene 2011, 30:2282-2288.
15. Demidova A.R., Aau M.Y., Zhuang L., Yu Q. Dual regulation of Cdc25A by Chk1 and p53-ATF3 in DNA replication checkpoint control. J. Biol. Chem. 2009, 284:4132-4139.
16. Dutertre M., Sanchez G., De Cian M.C., Barbier J., Dardenne E., Gratadou L., Dujardin G., Le Jossic-Corcos C., Corcos L., Auboeuf D. Cotranscriptional exon skipping in the genotoxic stress response. Nat. Struct. Mol. Biol. 2010, 17:1358-1366.
17. Filippov V., Filippova M., Duerksen-Hughes P.J. The early response to DNA damage can lead to activation of alternative splicing activity resulting in CD44 splice pattern changes. Cancer Res. 2007, 67:7621-7630.
18. Filippov V., Schmidt E.L., Filippova M., Duerksen-Hughes P.J. Splicing and splice factor SRp55 participate in the response to DNA damage by changing isoform ratios of target genes. Gene 2008, 420:34-41.
19. Forrest A.R.R., McCormack A.K., DeSouza C.P.C., Sinnamon J.M., Tonks I.D., Hayward N.K., Ellem K.A.O., Gabrielli B.G. Multiple splicing variants of cdc25B regulate G2/M progression. Biochem. Biophys. Res. Commun. 1999, 260:510-515.
20. Guo J., Kleeff J., Li J., Ding J., Hammer J., Zhao Y., Giese T., Korc M., Büchler M.W., Friess H. Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma. Oncogene 2004, 23:71-81.
21. Hernández S., Bessa X., Beà S., Hernández L., Nadal A., Mallofré C., Muntane J., Castells A., Fernández P.L., Cardesa A., Campo E. Differential expression of cdc25 cell-cycle activating phosphatases in human colorectal carcinoma. Lab. Invest. 2001, 81:465-473.
22. Hernández S., Hernández L., Beà S., Pinyol M., Nayach I., Bellosillo B., Nadal A., Ferrer A., Fernández P.L., Montserrat E., Cardesa A., Campo E. Cdc25A and the splicing variant cdc25B2, but not cdc25B1, -B3 or -C, are over-expressed in aggressive human non-Hodgkin's lymphomas. Int. J. Cancer (Pred. Oncol.) 2000, 89:148-152.
23. Jackson S.P., Bartek J. The DNA-damage response in human biology and disease. Nature 2009, 461:1071-1078.
24. Jinno S., Suto K., Nagata A., Igarashi M., Kanaoka Y., Nojima H., Okayama H. CDC25A is a novel phosphatase functioning early in the cell cycle. EMBO J. 1994, 13:1549-1556.
25. Kaklamani V.G., Gradishar W.J. Adjuvant therapy of breast cancer. Cancer Invest. 2005, 23:548-560.
26. Karlsson-Rosenthal C., Millar J.B.A. Cdc25: mechanisms of checkpoint inhibition and recovery. Trends Cell. Biol. 2006, 16:285-292.
27. Kieffer I., Lorenzo C., Dozier C., Schmitt E., Ducommun B. Differential mitotic degradation of the CDC25B phosphatase variants. Oncogene 2007, 26:7847-7858.
28. Komarov P.G., Komarova E.A., Kondratov R.V., Christov-Tselkov K., Coon J.S., Chernov M.V., Gudkov A.V. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999, 285:1733-1737.
29. Kristjánsdóttir K., Rudolph J. Cdc25 phosphatases and cancer. Chem. Biol. 2004, 11:1043-1051.
30. Lammer C., Wagerer S., Saffrich R., Mertens D., Ansorge W., Hoffmann I. The cdc25B phosphatase is essential for the G2/M phase transition in human cells. J. Cell. Sci. 1998, 111:2445-2453.
31. Lents N.H., Wheeler L.W., Baldassare J.J., Dynlacht B.D. Identification and characterization of a novel Mdm2 splice variant acutely induced by the chemotherapeutic agents adriamycin and actinomycin D. Cell Cycle 2008, 7:1580-1586.
32. Mah L.-J., El-Osta A., Karagiannis T.C. γH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 2010, 24:679-686.
33. Markey M., Berberich S.J. hdmX transcripts decrease following genotoxic stress. Oncogene 2008, 27:6657-6666.
34. Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R., Hurov K.E., Luo J., Bakalarsk I.C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007, 316:1160-1166.
35. Millar J.B.A., Blevitt J., Gerace L., Sadhu K., Featherstone C., Russell P. p55CDC25 is a nuclear protein required for the initiation of mitosis in human cells. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:10500-10504.
36. Muñoz M.J., Pérez S.M.S., Paronetto M.P., de la Mata M., Pelisch F., Boireau S., Glover-Cutter K., Ben-Dov C., Blaustein M., Lozano J.J., Bird G., Bentley D., Bertrand E., Kornblihtt A.R. DNA damage regulates alternative splicing through inhibition of RNA polymerase II elongation. Cell 2009, 137:708-720.
37. Ozen M., Ittmann M. Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer. Clin. Cancer Res. 2005, 11:4701-4706.
38. Pajares M.J., Ezponda T., Catena R., Calvo A., Pio R., Montuenga L.M. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol. 2007, 8:349-357.
39. Sarkaria J.N., Busby E.C., Tibbetts R.S., Roos P., Taya Y., Karnitz L.M., Abraham R.T. Inhibition of ATM and ATR kinase activities by the radiosansitizing agent, caffeine. Cancer Res. 1999, 59:4375-4382.
40. Shkreta L., Michelle L., Toutant J., Tremblay M.L., Chabot B. The DNA damage response pathway regulates the alternative splicing of the apoptotic mediator Bcl-x. J. Biol. Chem. 2010, 286:331-340.
41. Solier S., Lansiaux A., Logette E., Wu J., Soret J., Tazi J., Bailly C., Desoche L., Solary E., Corcos L. Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells. Mol. Cancer Res. 2004, 2:53-61.
42. Soule H.D., Vasquez J., Long A., Albert S., Brennan M.A. Human cell line from a pleural effusion derived from a breast carcinoma. J. Natl. Cancer I 1973, 51:1409-1416.
43. St.Clair S., Giono L., Varmeh-Ziaie S., Resnick-Silverman L., Liu W., Padi A., Dastidar J., DaCosta A., Mattia M., Manfredi J.J. DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. Mol. Cell. 2004, 16:725-736.
44. Varmeh S., Manfredi J.J. Overexpression of the dual specificity phosphatase, Cdc25C, confers sensitivity on tumor cells to doxorubicin-induced cell death. Mol. Cancer Ther. 2008, 7:3789-3799.
45. Wang E.T., Sandberg R., Luo S., Khrebtukova I., Zhang L., Mayr C., Kingsmore S.F., Schroth G.P., Burge C.B. Alternative isoform regulation in human tissue transcriptomes. Nature 2008, 456:470-476.
46. Wang Y., Dean J.L., Millar E.K.A., Tran T.H., McNeil C.M., Burd C.J., Henshall S.M., Utama F.E., Witkiewicz A., Rui H., Sutherland R.L., Knudsen K.E., Knudsen E.S. Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Res. 2008, 68:5628-5638.
47. Wang Z., Trope C.G., Florenes V.A., Suo Z., Nesland J.M., Holm R. Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes. BMC Cancer 2010, 10:233.
48. Wegener S., Hampe W., Herrmann D., Schaller H.C. Alternative splicing in the regulatory region of the human phosphatases CDC25A and CDC25C. Eur. J. Cell. Biol. 2000, 79:810-815.
49. Whelan R.D., Waring C.J., Wolf C.R., Hayes J.D., Hosking L.K., Hill B.T. Overexpression of p-glycoprotein and glutathione S-transferase pi in MCF-7 cells selected for vincristine resistance in vitro. Int. J. Cancer 1992, 52:241-246.